Related Experiment Video
Updated: Jul 11, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Accelerated atherosclerosis in rheumatoid arthritis
Zoltán Szekanecz1, György Kerekes, Henriett Dér
1Division of Rheumatology, Third Department of Medicine, University of Debrecen Medical and Health Science Center, Debrecen, Hungary. szekanecz@iiibel.dote.hu
Insights
Rheumatoid arthritis (RA) patients face higher cardiovascular risks due to inflammation. Early detection of endothelial dysfunction and atherosclerosis through specific markers and imaging can help manage this risk.
Area of Science:
- Rheumatology
- Cardiology
- Immunology
Background:
- Cardiovascular disease is a primary cause of mortality in rheumatoid arthritis (RA).
- Endothelial dysfunction and atherosclerosis are key contributors to cardiovascular risk in RA patients.
- Both traditional risk factors and inflammation-specific mechanisms drive vascular disease in RA.
Purpose of the Study:
- To investigate the role of endothelial dysfunction and atherosclerosis in RA.
- To identify key imaging and laboratory markers for early detection of vascular disease in RA.
- To explore strategies for minimizing cardiovascular risk in RA patients.
Main Methods:
- Assessment of common carotid intima-media thickness (ccIMT) and flow-mediated vasodilation (FMD).
- Evaluation of immunological markers such as anti-CCP antibodies and pro-inflammatory cytokines (TNF-alpha, IL-6).
- Analysis of metabolic markers including homocysteine, dyslipidemia, folate, vitamin B12, and paraoxonase activity.
Main Results:
- RA patients exhibit increased ccIMT and impaired FMD, indicating endothelial dysfunction and atherosclerosis.
- Various immunological and metabolic factors are implicated in the development of vascular disease in RA.
- Early diagnostic markers and therapeutic interventions are crucial for managing cardiovascular risk.
Conclusions:
- Early detection of endothelial dysfunction and atherosclerosis in RA is feasible using imaging and laboratory markers.
- Comprehensive management strategies, including immunosuppressive therapy and lifestyle changes, are essential.
- Close monitoring of RA patients can significantly reduce their cardiovascular risk.
Abstract:
Cardiovascular disease is a leading cause of mortality in rheumatoid arthritis (RA). Endothelial dysfunction often precedes manifest atherosclerosis. Both traditional, Framingham risk factors and inflammation-associated factors are involved in RA-associated atherosclerosis. Among imaging techniques, the early determination of common carotid intima-media thickness (ccIMT), flow-mediated vasodilation (FMD), and nitroglycerine-mediated vasodilation (NMD) may be useful to determine atherosclerosis and endothelial dysfunction. We and others found increased ccIMT and impaired FMD in RA patients. Among immunological and metabolic laboratory markers, anticyclic citrullinated peptide (anti-CCP) antibodies, IgM rheumatoid factor, circulating immune complexes, pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), Th0/Th1 T cells, homocysteine, dyslipidemia, decreased folate and vitamin B12 production, and impaired paraoxonase activity may all be involved in the development of vascular disease in RA. The early diagnosis of endothelial dysfunction and atherosclerosis, active immunosuppressive treatment, the use of drugs that control atherosclerosis, changes in sedentary lifestyle, and the close follow-up of RA patients may help to minimize cardiovascular risk in these individuals.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Atherosclerosis I: Introduction
Atherosclerosis III: Management
Inflammation
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis IV: Nursing Management
